Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch Study of Infliximab (Remicade) in Patients With Active Rheumatoid Arthritis Inadequately Responding to Etanercept or Adalimumab
2007-003288-36Phase 4Terminated
- Sponsor
- Janssen Biotech
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-blind, single-arm trial of infliximab in rheumatoid arthritis (RA), sponsored by Janssen Biotech. Primary endpoint: EULAR response at week 10. Started Jul 2008; status: terminated.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-003288-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003288-36.